Remben Talaban

Scientific Investigator and GSK Fellow
GlaxoSmithKline
Philipp Nold
Prior to joining GlaxoSmithKline in 2014 as a member of the Biopharm Process Research (BPR) Disruptive Technologies Team, Remben worked at Great Ormond Street Hospital NE Thames Regional Genetics Service looking into patients with various genetic disorders such as Duchenne Muscular Dystrophy, cystic fibrosis, cases of aneuploidy, fertility problems and children with development delay. Remben joined GSK in 2014 bringing with him extensive experience in molecular cytogenetics from his previous employment at St. Lukes Medical Centres Cytogenetics Department, Great Ormond Street Hospital, and also at The Institute of Cancer Research. His efforts in establishing a cytogenetics laboratory and subsequent embedding of conventional and advanced fluorescence in situ hybridisation (FISH) techniques have afforded GSK an unparalleled and in-depth understanding of their cell lines aiding the rational design of their next generation CHO platforms. Building on this, he is currently exploring new novel technologies using other microscopy methods and developing innovative new ways of working, ensuring BPR is fully equipped in the ever-changing bioprocessing landscape.

Sessions

October 30 2019, 11:30
 - 12:00
Leveraging Molecular Cytogenetics In Mammalian Cell Line Development